Objective Each year in Europe, lung diseases are responsible of more than one million deaths and extensive costs estimated at €380 billion. These respiratory diseases, such as chronic obstructive pulmonary disease, lung cancer, asthma and tuberculosis, are very difficult to detect and usually diagnosed in late-stages once there is a significant burden of disease within them. BREATH project consists to develop, manufacture and market a research instrument to study and to diagnose respiratory diseases. The concept is based on a completely new method to collect and analyse particles via exhaled air in the small airways to easily identify chemical changes and potential biomarkers for respiratory diseases. The PExA method has the potential to fundamentally change the way lung diseases are diagnosed and treated today by offering a best alternative of the existing methods on market, which brings a substantial commercial potential. By doing a simple breathing test and without any potential risk for the patients, PExA's instrument provides a quantitative, reliable, user friendly, non-invasive, less painful, faster, repeatable method for early-stage diagnosis. PExA's clients are all those who are currently actively looking for biomarkers to figure out the patient's health conditions such as lung researchers and healthcare professionals within health services, academia and pharmaceutical companies initially in the EU and then the US. The objectives of BREATH project Phase1 are to: (1) prove through a feasibility study the potential to develop a real-time and stand-alone analysis/diagnostic device; (2) enhance the competitiveness and profitability of the service by improving the quality and reliability of the system via (i) the checking system, (ii) designing and developing our own disposable kits. The outcome will be a feasibility study assessing the socio-economic, commercial and technical aspects of the innovation that will be used to define the activities of Phase II. Fields of science medical and health sciencesclinical medicinepneumologyasthmamedical and health sciencesclinical medicineoncologylung cancernatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesclinical medicinepneumologytuberculosismedical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses Programme(s) H2020-EU.2.1.4. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Topic(s) SMEInst-03-2016-2017 - Dedicated support to biotechnology SMEs closing the gap from lab to market Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-1-2016-2017 Funding Scheme SME-1 - SME instrument phase 1 Coordinator PEXA AB Net EU contribution € 50 000,00 Address ARVID WALLGRENS BACKE 20 413 46 GOTEBORG Sweden See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Södra Sverige Västsverige Västra Götalands län Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
